Aclaris Therapeutics (NASDAQ:ACRS) Upgraded to “Hold” by Zacks Investment Research

Zacks Investment Research upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a sell rating to a hold rating in a report published on Friday, Zacks.com reports.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

Several other equities analysts also recently weighed in on ACRS. Cantor Fitzgerald reiterated a buy rating and issued a $50.00 price target on shares of Aclaris Therapeutics in a report on Friday, March 15th. ValuEngine upgraded shares of Aclaris Therapeutics from a sell rating to a hold rating in a report on Monday, April 1st. BidaskClub upgraded shares of Aclaris Therapeutics from a strong sell rating to a sell rating in a report on Wednesday, April 24th. Leerink Swann started coverage on shares of Aclaris Therapeutics in a report on Monday, May 6th. They issued an outperform rating on the stock. Finally, Svb Leerink started coverage on shares of Aclaris Therapeutics in a report on Monday, May 6th. They issued an outperform rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The company has an average rating of Hold and an average target price of $19.69.

Shares of NASDAQ:ACRS opened at $2.19 on Friday. Aclaris Therapeutics has a twelve month low of $1.93 and a twelve month high of $21.97. The stock has a 50 day simple moving average of $4.89. The company has a current ratio of 4.33, a quick ratio of 4.30 and a debt-to-equity ratio of 0.16. The firm has a market cap of $90.38 million, a P/E ratio of -0.54 and a beta of 1.48.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.05). Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%. The business had revenue of $5.04 million during the quarter, compared to analyst estimates of $5.13 million. On average, research analysts anticipate that Aclaris Therapeutics will post -2.98 EPS for the current year.

In other news, major shareholder James E. Flynn sold 454,261 shares of the firm’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $4.59, for a total transaction of $2,085,057.99. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder James E. Flynn sold 339,537 shares of the firm’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $4.62, for a total transaction of $1,568,660.94. The disclosure for this sale can be found here. Insiders have sold a total of 1,408,508 shares of company stock worth $7,421,891 in the last ninety days. Corporate insiders own 14.80% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Rhumbline Advisers grew its stake in shares of Aclaris Therapeutics by 50.6% in the 4th quarter. Rhumbline Advisers now owns 39,490 shares of the biotechnology company’s stock valued at $292,000 after buying an additional 13,269 shares during the period. Prudential Financial Inc. acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $198,000. BlackRock Inc. grew its stake in shares of Aclaris Therapeutics by 43.8% in the 4th quarter. BlackRock Inc. now owns 3,620,835 shares of the biotechnology company’s stock valued at $26,759,000 after buying an additional 1,103,423 shares during the period. Citigroup Inc. grew its stake in shares of Aclaris Therapeutics by 3,200.0% in the 4th quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 3,872 shares during the period. Finally, Northern Trust Corp lifted its position in Aclaris Therapeutics by 25.6% in the 4th quarter. Northern Trust Corp now owns 444,942 shares of the biotechnology company’s stock valued at $3,288,000 after acquiring an additional 90,791 shares in the last quarter. Hedge funds and other institutional investors own 91.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Recommended Story: Special Dividends

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.